Editas Medicine Archives

In Depth 11 Jun 2025

Can gene therapy treat vision loss?

Since the approval of Luxturna, there has been a wave of companies developing treatments with the potential to cure different forms of genetic blindness.

June 11, 2025 - 12 minutesmins - By Roohi Mariam Peter

In Depth 11 Feb 2019

CRISPR: One Patent to Rule Them All

The gene editing tool CRISPR-Cas9 has revolutionized research in biology. With several parties fighting for the rights to the technology’s intellectual property, how difficult is it for third parties to access this coveted technology? The CRISPR patent dispute is quite unique. While universities usually work together to disseminate innovation and knowledge, in the CRISPR case […]

February 11, 2019 - 5 minutesmins - By Timothé Cynober

Allergan Editas Medicine CRISPR eye disease

News and Trends 15 Mar 2017

Allergan makes a deal with Editas to License CRISPR Programs for Eye Disease

Allergan has signed a deal with Editas Medicine to access its CRISPR technology and license up to five of its programs in ocular disease. The Irish Allergan has a certain tendency to go on shopping sprees. Its latest deal is a research and development alliance with the American Editas Medicine, which is on the side of […]

March 15, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 16 Feb 2017

The Patent Office has Spoken: What does it Mean for CRISPR in Europe?

The US Patent Office has ruled that the Broad Institute’s CRISPR patents do not interfere with those from UC Berkeley. While this might sound like everybody wins, it’s actually a loss for Charpentier and the CRISPR Therapeutics team. CRISPR has been hailed as the ‘scientific discovery of the century’. This molecular technique could be used […]

February 16, 2017 - 4 minutesmins - By Clara Rodríguez Fernández

News and Trends 8 Dec 2016

UPDATE: No Clear Winner in the CRISPR Patent Battle

Today marks an inflection point in the future of medicine: both parties fighting for the ownership of CRISPR have made their oral arguments in front of a jury. Who will win the rights to exploit a technology that could be used to cure any genetic disease? CRISPR has been hailed as the ‘scientific discovery of the […]

December 8, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 15 Nov 2016

How much of a Gamble is Investing in CRISPR?

CRISPR is going to change a lot in the life science industry and is perceived as THE discovery of the 21st century. Within the past 6 months, 3 companies went public, raising between €50M and €100M each (with valuation close to the billion), to bring about the CRISPR revolution. But the problem is, there is absolutely […]

November 15, 2016 - 4 minutesmins - By Philip Hemme

News and Trends 12 Sep 2016

CRISPR Therapeutics applies to go Public in another Massive IPO

The wait is over: CRISPR Therapeutics has turned up the heat on its rivals with an IPO filing of €80M, but this figure could be a lowball. Everyone saw it coming – the only question was, when would CRISPR Therapeutics file for an IPO? News arrived today that the company had finally applied to the US […]

September 12, 2016 - 3 minutesmins - By Evelyn Warner

News and Trends 5 Jul 2016

“CRISPR is highly fragmented, with too many approaches. We bring it all together”

The problem with CRISPR, is that not many people are actually experts in the field, and there are only a select few who worked on it pre-2013. So how did this UK Startup make a big name for itself in field of the ‘Biotech Breakthrough of the Century’? Desktop Genetics is a startup founded in 2012 by three […]

July 5, 2016 - 4 minutesmins - By Dani Bancroft

News and Trends 30 Sep 2015

CRISPR Patent war to End after the Discovery of a New Editing Protein other than Cas9?

CRISPR is already revolutionizing Biotechnology. However, like every biotech revolution, there then follows a patent war. But the discovery of a new gene editing protein (Cpf1), with the potential of replacing Cas9, could change this status-quo. As Business Insider puts its, CRISPR is “the biggest biotech discovery of the century“. And its true, it really changed […]

September 30, 2015 - 3 minutesmins - By Philip Hemme

News and Trends 16 Sep 2015

Desktop Genetics bags €1.87M from top UK business angels to change how you manage your CRIPSR experiments

Gene Editing has been made much easier thanks to CRISPR but managing your genome editing workflow can be a challenge. London-based Desktop Genetics wants to solve this problem and just raised additional funding to accelerate its development. CRISPR is already considered as the biotech revolution of this century. Having an easy tool is one thing, but being […]

September 16, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 12 Aug 2015

CRISPR Therapeutics reinforces its Team with Top Executives from Pfizer and McKinsey

A new strategic movement in the hot CRISPR field: CRISPR Therapeutics ramps up its leadership team with Samarth Kulkarni as its new Chief Business Officer and Michael Bruce as Senior Vice President to moderate program portfolio and alliance management. In the meantime, CRISPR’s main competitor EditasMedicine procured €108M to accelerate its CRISPR-based therapies in clinical state. […]

August 12, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 18 Jun 2015

German Viral Vector Producer SIRION pursues its American dream and opens in Boston

The biggest biocluster of the World is still attractive. Munich-based Sirion Biotech decided to open an office to establish its US presence and benefit from Boston’s leading position in the gene therapy field. Gene Therapy is the next big thing in Biotech and is now moving from a theoretical dream to reality. Boston is clearly the hotspot for […]

June 18, 2015 - 2 minutesmins - By Philip Hemme

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Editas Medicine

Can gene therapy treat vision loss?

CRISPR: One Patent to Rule Them All

Allergan makes a deal with Editas to License CRISPR Programs for Eye Disease

The Patent Office has Spoken: What does it Mean for CRISPR in Europe?

UPDATE: No Clear Winner in the CRISPR Patent Battle

How much of a Gamble is Investing in CRISPR?

CRISPR Therapeutics applies to go Public in another Massive IPO

“CRISPR is highly fragmented, with too many approaches. We bring it all together”

CRISPR Patent war to End after the Discovery of a New Editing Protein other than Cas9?

Desktop Genetics bags €1.87M from top UK business angels to change how you manage your CRIPSR experiments

CRISPR Therapeutics reinforces its Team with Top Executives from Pfizer and McKinsey

German Viral Vector Producer SIRION pursues its American dream and opens in Boston

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!